Basic, translational and clinical aspects of bronchiectasis in adults
- PMID: 37286220
- PMCID: PMC10245133
- DOI: 10.1183/16000617.0015-2023
Basic, translational and clinical aspects of bronchiectasis in adults
Abstract
Bronchiectasis is a common progressive respiratory disease with recognisable radiological abnormalities and a clinical syndrome of cough, sputum production and recurrent respiratory infections. Inflammatory cell infiltration into the lung, in particular neutrophils, is central to the pathophysiology of bronchiectasis. Herein we explore the roles and relationships between infection, inflammation and mucociliary clearance dysfunction in the establishment and progression of bronchiectasis. Microbial and host-mediated damage are important processes underpinning bronchiectasis and the relative contribution of proteases, cytokines and inflammatory mediators to the propagation of inflammation is presented. We also discuss the emerging concept of inflammatory endotypes, defined by the presence of neutrophilic and eosinophilic inflammation, and explore the role of inflammation as a treatable trait. Current treatment for bronchiectasis focuses on treatment of underlying causes, enhancing mucociliary clearance, controlling infection and preventing and treating complications. Data on airway clearance approaches via exercise and mucoactive drugs, pharmacotherapy with macrolides to decrease exacerbations and the usefulness of inhaled antibiotics and bronchodilators are discussed, finishing with a look to the future where new therapies targeting host-mediated immune dysfunction hold promise.
Copyright ©The authors 2023.
Conflict of interest statement
Conflict of interest: J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis and Insmed, outside the submitted work; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer and Zambon, outside the submitted work. Conflict of interest: S. Elborn holds a joint public–private grant from the European commission in the innovative medicines initiative with Novartis AG and Spexsis; he worked as a paid consultant for Vertex Pharmaceuticals and Viatris Inc.; and has been a paid speaker for many pharmaceutical companies over 30 years in respiratory medicine. Conflict of interest: C.M. Greene reports grants or contracts from NIH and Vertex, outside the submitted work; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Vertex, outside the submitted work; support for attending meetings and/or travel from European Respiratory Society, outside the submitted work; and was Head of ERS Assembly 3 2019–2022, outside the submitted work.
Figures
Similar articles
-
Bronchiectasis management in adults: state of the art and future directions.Eur Respir J. 2024 Jun 28;63(6):2400518. doi: 10.1183/13993003.00518-2024. Print 2024 Jun. Eur Respir J. 2024. PMID: 38782469 Free PMC article. Review.
-
Advances in pharmacotherapy for bronchiectasis in adults.Expert Opin Pharmacother. 2023 Jun;24(9):1075-1089. doi: 10.1080/14656566.2023.2210763. Epub 2023 May 9. Expert Opin Pharmacother. 2023. PMID: 37161410 Review.
-
Bronchiectasis.Nat Rev Dis Primers. 2018 Nov 15;4(1):45. doi: 10.1038/s41572-018-0042-3. Nat Rev Dis Primers. 2018. PMID: 30442957 Review.
-
Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?Drugs. 2007;67(7):965-74. doi: 10.2165/00003495-200767070-00002. Drugs. 2007. PMID: 17488142 Review.
-
Macrolide antibiotics for bronchiectasis.Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012406. doi: 10.1002/14651858.CD012406.pub2. Cochrane Database Syst Rev. 2018. PMID: 29543980 Free PMC article. Review.
Cited by
-
Clarithromycin Modulates Neutrophilic Inflammation Induced by Prevotella intermedia in Human Airway Epithelial Cells.Antibiotics (Basel). 2024 Sep 23;13(9):909. doi: 10.3390/antibiotics13090909. Antibiotics (Basel). 2024. PMID: 39335081 Free PMC article.
-
microRNAs: a new class of endogenous antimicrobials for the treatment of infections in cystic fibrosis and beyond.Future Microbiol. 2024 Aug 12;19(12):1041-1043. doi: 10.1080/17460913.2024.2357971. Epub 2024 Aug 6. Future Microbiol. 2024. PMID: 39105666 No abstract available.
-
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.ERJ Open Res. 2024 Jul 22;10(4):00151-2024. doi: 10.1183/23120541.00151-2024. eCollection 2024 Jul. ERJ Open Res. 2024. PMID: 39040578 Free PMC article.
-
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for Pseudomonas aeruginosa eradication in bronchiectasis: ERASE.ERJ Open Res. 2024 Feb 26;10(1):00938-2023. doi: 10.1183/23120541.00938-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38410702 Free PMC article.
-
Antibiotic resistance, bacterial transmission and improved prediction of bacterial infection in patients with antibody deficiency.JAC Antimicrob Resist. 2023 Dec 14;5(6):dlad135. doi: 10.1093/jacamr/dlad135. eCollection 2023 Dec. JAC Antimicrob Resist. 2023. PMID: 38098890 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources